Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „received“
Suchtreffer
Begriffe & Kennungen
Benlysta · 4.8 · In a 52-week open-label study in which 25 paediatric patients (10 to 17 years of age) with SLE received subcut
Eintrag öffnenBenlysta · 4.8 · In a 52-week open-label study in which 25 paediatric patients (10 to 17 years of age) with SLE received subcut
Eintrag öffnenBenlysta · 4.8 · In a 52-week placebo-controlled study in which 53 patients (6 to 17 years of age) with SLE received Benlysta (
Eintrag öffnenBenlysta · 4.8 · In a 52-week placebo-controlled study in which 53 patients (6 to 17 years of age) with SLE received Benlysta (
Eintrag öffnenBenlysta · 4.8 · In a 52-week placebo-controlled study in which 53 patients (6 to 17 years of age) with SLE received Benlysta (
Eintrag öffnenBesponsa · 4.8 · In adult patients who received BESPONSA, the most common (≥ 2%) serious adverse reactions were infection (23%)
Eintrag öffnenBesponsa · 4.8 · Regarding other risk factors, VOD/SOS was reported in 6/11 (55%) patients who received a HSCT conditioning reg
Eintrag öffnenBesponsa · 4.8 · Table 5 shows the adverse reactions reported in adult patients with relapsed or refractory ALL who received BE
Eintrag öffnenBetmiga · 4.8 · The safety of Betmiga was evaluated in 8 433 adult patients with OAB, of which 5 648 received at least one dos
Eintrag öffnenBetmiga · 4.8 · The safety of mirabegron tablets was evaluated in 8 433 adult patients with OAB, of which 5 648 received at le
Eintrag öffnenBexsero · 4.8 · In addition to reports in clinical trials, worldwide voluntary reports of adverse reactions received for Bexse
Eintrag öffnenBeyfortus · 4.8 · Table 1 presents the adverse reactions reported in 2 966 term and preterm infants (GA ≥29 weeks) who received
Eintrag öffnenBosulif · 4.8 · A total of 1 372 leukaemia adult patients received at least 1 dose of single-agent bosutinib. The median durat
Eintrag öffnenBosulif · 4.8 · A total of 55 paediatric patients ≥ 1 year of age received at least 1 dose of bosutinib in the Phase I/II, mul
Eintrag öffnenBrinavess · 4.5 · Vernakalant must not be administered in patients who received intravenous AADs (class I and III) within 4 hour
Eintrag öffnenCabometyx · 4.8 · Description of selected adverse reactions Data for the following reactions are based on patients who received
Eintrag öffnenCancidas (previously Caspofungin MSD) · 4.8 · Adult patients In clinical studies, 1,865 adult individuals received single or multiple doses of caspofungin:
Eintrag öffnenCatiolanze · 4.8 · Long term safety data are available from a Phase 3 study in which 118 patients received Catiolanze at least fo
Eintrag öffnenCayston · 4.8 · In the two Phase 3 placebo-controlled clinical studies where patients received Cayston for 28 days, the most f
Eintrag öffnenCervarix · 4.5 · In all clinical trials individuals who had received immunoglobulin or blood-derived products within 3 months p
Eintrag öffnen